A metaanalysis identified that frailty, whether measured by the frail index or frail phenotype, was associated with a higher risk of developing prema ture mortality, prolonged hospitalization, being institutionalized, having disability in basic or instrumental activities of daily living (ADLs), falls, fractures, cognitive impairment, and greater healthcare resource utilization. 5 Similar findings have been corroborated by other. 6, 7 Conversely, several factors, including, but not limited to, bio logic aging, genetic background, lifestyle factors, cardiovascular morbidities, and dietary and nutri tional balances, play a role in the pathogenesis of frailty in the geriatric population. 8, 9 Frailty in patients with chronic kidney disease The importance of frailty has also been acknowl edged in patients with other chronic disorders irrespective of age, including those with chronic kidney disease (CKD) and endstage renal disease (ESRD). The presence of frailty increases the risk of mortality in these patients, and its adverse influ ences in other healthrelated outcomes are being discovered. A previous systematic review of 30 reports focused on the relationship between func tional, cognitive impairment or frailty, and adverse outcomes in patients with predialysis CKD or dialysisdependent ESRD. 10 The authors found that in these patients, functional impairment or frailty was consistently associated with a signifi cantly higher risk of mortality or hospitalization. Another narrative review reached a similar conclu sion regarding the negative effects of frailty on sur vival of ESRD patients. 11 However, accumulating evidence suggests other frailtyrelated adverse effects besides mortality and hospitalization of CKD patients, although this has not been con firmed to date. A comprehensive understanding of the biology of frailty in CKD patients, including its risk factors, accompanying features, and com plications, is therefore needed to facilitate the design of intervention strategies in this dispropor tionately affected population. In this review, we summarize evidence from the literature to answer this gap in existing knowledge.
Strategy of literature search
We used a systematic approach to identify rele vant articles assessing frailty in patients with all stages of CKD in their titles or abstract using key words, such as 'frailty' or 'frail phenotype', and 'chronic kidney disease', 'renal insufficiency', 'chronic renal failure', 'endstage renal disease', or 'chronic dialysis', from databases, including PubMed, MEDLINE, and Google Scholar. Reports between 1980 and 28 February 2019 were retrieved. Inclusion criteria were original reports involving adult human subjects that exam ined the relationship between frailty and any types of clinical features or outcomes among the target population of CKD. Eligible studies were inde pendently reviewed by two reviewers (P.Y.W. and C.T.C.). We excluded review articles, articles without abstract available, those that failed to measure the effects of frailty in CKD patients, or nonCKD target population ( Figure 1 ). We fur ther screened the abstracts and reference lists of the retrieved articles to identify additional studies that contained original data focusing on the same issue. Any discrepancy between the two reviewers was resolved by discussing with another senior author (D.C.C.). CKD (nondialysis) was mostly defined according to the estimated glomerular fil tration rate based on the Modification of Diet in Renal Disease, while very few CKD cases were evaluated based on elevated serum creatinine lev els. Staging of CKD, whichever available, was performed based on the Kidney Disease Improving Global Outcome criteria. 12 We extracted the following parameters from the included studies: publication data, participants' baseline CKD stages, method of frailty measure ment, results from univariate analyses of clinical features between frail and nonfrail participants, and multivariate analyses of frail associates or complications, depending on the study design. We tabulated the study characteristics into the following categories: unadjusted risk associates of frailty, adjusted potential causes of frailty, and adjusted risks of health outcomes conferred by frailty according to the biologic relationship between frailty and clinical features that were extracted. Factors adjusted for in the multivariate analyses included at least age and gender in all studies and could further include studyspecific parameters such as comorbidity, anthropometric data, and laboratory profiles.
Overview of studies addressing frailty influences in CKD patients
Our database search identified 537 articles addressing frailty and CKD in whole or in part.
After an initial screening of the title and abstract, we excluded review articles, those without abstract available, those discussing frailty literally without direct measurement of frailty, and those that did not measure frailty in CKD patients ( Figure 1 ). Overall, 62 original investigation arti cles with their full text (or abstract if published as conference proceedings) were finally reviewed with results extracted for summarization. We found that nearly half of these investigations were conducted in the United States (n = 28, 45.2%), followed by Taiwan (n = 7, 11.3%), Canada (n = 4, 6.5%), and Brazil (n = 4, 6.5%). Among the 62 articles, 58.1% used a cohort study design with follow up, while 41.9% had a crosssectional design; more than half of the articles (n = 37; 59.7%) were based on singlecenter data, whereas others were analyzed using b multicenter regis tries. ESRD patients undergoing chronic hemodi alysis (stage 5D) (n = 28; 45.2%) were the most common population being evaluated, followed by patients with nondialysis CKD (n = 12; 19.4%), those receiving renal transplantation (stage 5T) (n = 11; 17.7%), and ESRD patients receiving either hemodialysis or peritoneal dialysis (n = 8; 12.9%). Most retrieved studies used the Fried phenotype with or without modifications to meas ure frailty, whereas seven (11.3%) and four (6.5%) defined frailty according to the FRAIL scale and the Edmonton frail scale, respectively.
Among the 62 articles, 79% (n = 49) included univariate analyses of the relationship between frailty and risk features among CKD patients and 83.9% (n = 52) conducted multivariate analyses to account for influences from confounders. Most of the retrieved studies addressed frailtyrelated adverse complications in these patients (n = 45; 72.6%), whereas six (9.75%) evaluated potential contributors and complications in the same study; nine (14.5%) of the retrieved studies examined potential contributors to frailty only.
In the following section, we summarize findings from the 62 articles according to the role of each factor in CKD patients into four sections: unad justed frailty associates, potential contributors to frailty (adjusted), potential modifiers of frailty course (adjusted), and healthrelated outcomes affected by frailty (adjusted).
Unadjusted associates of frailty in CKD patients
Existing literature examined a diverse spectrum of risk associates accompanying frailty in CKD patients ( Supplementary Table) , including demo graphic factors, anthropometric parameters, mul tiple types of comorbidity, psychological illnesses, physical examination parameters, nutrition, body composition details, bone mineral density, labo ratory data, duration and clinical features of dial ysis, residual renal function, ADL, quality of life (QoL), and functional and overall outcomes. Higher age; larger waist circumference; lower blood pressure; higher prevalence of comorbidi ties (heart failure, peripheral vascular disease, diabetes, and obesity); greater fat mass but less lean mass and bone mass; lower serum albumin, hemoglobin, and cholesterol levels but higher cre atinine and Creactive protein (CRP) levels; less residual renal function; worse cognitive function; lower frequency of physical activity and worse ADL; poorer nutrition and QoL; and a higher degree of healthcare utilization were consistently found in frail CKD patients compared with those in nonfrail CKD ones. However, these relation ships were all unadjusted, and only some of them have been validated in multivariate analyses, as detailed in the following sections.
Potential contributors to frailty in CKD patients
After adjustment for confounders, multiple fac tors emerged as independent contributors to the development of frailty in CKD patients ( Table 1) . Sociodemographic factors, including advanced age, female gender, certain ethnicity (nonWhite), unemployment, lower education, and smoking, particularly age and being female, are associated with a significantly higher risk of frailty among CKD patients than among nonfrail ones. Increasing CKD severity correlates with a higher frailty risk; however, a doseresponse relationship has not been consistently observed. Comorbidities such as the cardiovascular, pulmonary, and cen tral nervous system disorders, metabolic distur bance, and musculoskeletal disorders were all significant risk factors for developing frailty in CKD patients. Among these comorbidities, endothelial dysfunction, chronic obstructive pul monary disease, obesity, and arthritis were asso ciated with more than twofold risk elevation. Psychiatric impairment and disability were asso ciated with an even higher risk of frailty (more than threefold) relative to other contributors. Among patients undergoing chronic hemodialy sis, laboratory data such as hypocreatininemia, hypoalbuminemia, and low testosterone levels, with a similar degree of risk elevation, were pre dictors of developing frailty in CKD patients. A summary of potential causes of frailty in CKD patients is illustrated in Figure 2 .
Potential modifiers of frailty courses in CKD patients
Three of the retrieved studies examined factors that modified the course of frailty in CKD patients ( Table 2) . 26, 28, 40 Johansen and colleagues revealed that diabetes mellitus, certain ethnicity, and higher interleuin6 (IL6) levels were associated with worsening frailty over a 2year followup period among chronic dialysis patients, whereas higher serum albumin levels were associated with improv ing frailty. Chiang and colleagues reported that a baseline lower free testosterone level predicted the risk of developing frailty over 1 year among male dialysis patients. In contrast, in renal transplant patients, Chu and colleagues found that an AfricanAmerican origin was associated with improved frailty after transplantation, whereas diabetes and longer dialysis period predicted hav ing persistent frailty despite transplantation.
Established health-related complications owing to frailty in CKD patients
After confounder adjustment, frailty remained associated with multiple adverse complications in CKD patients, including disorders involving the cardiac, musculoskeletal, metabolic, and central nervous system; mental distress; impaired func tional status; increased fall risk; poorer QoL; greater utilization of healthcare resources (hospi talization, emergency visits, readmission, longer length of stay, and total medical visits); and a higher mortality than nonfrail CKD one patient (Table 3) . Specifically, frailty correlated indepen dently with abnormal cardiac conduction, lower lean and bone mass but higher adiposity, increased fracture risk, and worsened cognitive function.
Intere stingly, in patients undergoing chronic dial ysis, frailty conferred a 2.6fold higher risk of vascular access failure compared with nonfrail patients. 23 In addition, among renal transplant recipients, frailty significantly increased the risk of subsequent graft loss; those with frailty were more likely to have immunosuppressive dose reduction than nonfrail ones. 42, 54 Among the spectrum of frailtyrelated complications in CKD patients, the risk for having sarcopenia was the highest [odds ratio (OR) 12.2], 41 followed by any ADL impair ment (OR 11.3) 43 and renal allograft failure (OR 6.2). 42 The risk for fall in frail CKD patients was consistent among existing studies (differences in risk, 1.6 to 3), 32, 44, 50, 73 and a similar degree of risk increase was noted with regard to the endpoint of hospitalizationrelated events. 17, 37, 46, 51, 73 The relationship between frailty and mortality in CKD patients has been repeatedly examined in the literature (Table 3 ). Frailty is predictive of a higher risk of mortality in CKD patients across stages from early CKD to chronic dialysis or stage 5T patients, and the hazard ratios (HRs) ranged between 1.22 and 9.83 compared with nonfrail CKD patients, with most studies deriving a HR between 2 and 3. One study reported an exceptionally higher risk of mortality related to frailty (OR 9.83) 41 ; however, this likely resulted from the modest case number, the frailty meas urement approach (clinical frailty scale), and the population they examined (peritoneal dialysis). We also noted that the mortality risk conferred by frailty did not increase linearly with higher CKD severity based on the literature search results; however, mortality risk increased substantially among elderly compared with others. 47 This suggests that chronologic aging substantially enhances the adverse influence of frailty in CKD patients who already have accelerated biologic aging.
A brief summary of frailtyrelated adverse health related outcomes is illustrated in Figure 3 .
Reciprocal relationship between frailty and clinical features in CKD patients
Several features have been examined both as con tributors to and complications of frailty in CKD patients, with potential biologic plausibility. These risk features associated with frailty included hypoalbuminemia, higher fat mass, depression, and having a disability (Tables 1 and 3 ). In addi tion, it is interesting to note that having perma nent vascular access (fistula or graft) is predictive of a lower frailty risk, whereas frail patents were at a higher risk of access failure among chronic dial ysis patients. 23, 37 Similarly, musculoskeletal disor ders such as arthritis were independent causes of frailty in CKD patients, whereas frailty in CKD patients might contribute to a higher risk of fractures. 21, 72 Serum albumin level has long been considered a composite indicator for nutritional status, inflam matory status, and possibly beyond, exhibiting a strong outcomepredictive ability in diverse clini cal settings. 75 It is plausible that nutritional impairment contributes to an increased risk of frailty; conversely, the physical limitation imposed by frailty may further compromise nutrientseek ing ability and cause proteinenergy malnutrition in affected individuals with CKD. Alternatively, it can be that subclinical inflammation or cytokine interplay stays at the core of this albuminfrailty connection. 76 Dysfunctional muscle and fat tis sues with resultant metabolic defects, such as insulin resistance, are potential contributors to frailty and sarcopenia, and frailty can adversely affect eating behavior and lean mass building. 77 This vicious cycle is expected to perpetuate itself in CKD patients who are already at risk of deranged homeostasis with negative body compo sition alterations. Psychiatric disorders, particu larly depression, suppress one's appetite and decrease oral intake; moreover, frail individuals have poorer QoL and an increased risk of mood disorders. This bidirectional relationship between depression and frailty has been affirmed in older adults, 78 and likely still holds true in CKD patients. Disability and frailty frequently overlap in older adults, and crosstalk between these two adverse phenotypes exists and both indepen dently contribute and act synergistically to an increased risk of mortality among elderly and pos sibly CKD patients as well. 79
Factors that exhibit an opposite relationship with frailty in CKD patients
Among the retrieved reports, body mass index (BMI) exhibited an inverse relationship with the risk of frailty depending on the population being examined. Greater body BMI increases the prob ability of frailty in CKD patients regardless of Table 3 .
Confounder-adjusted risk of complications resulting from frailty in CKD patients. (Table 1) . A similar scenario has been reported by other studies involving the elderly, 80, 81 and may be explained partially by the close associa tion between better nutritional status and higher BMI in geriatric patients but not in the general population. It may be worthwhile to note that interventions directed toward reducing BMI can have differential influences in general CKD patients and in older ones.
Nonindependent risk features for frailty
The prevalence and values of many clinical fea tures differed significantly between CKD patients with and without frailty ( Supplementary Table) ; however, their relationship with frailty disappears after confounder adjustment. These factors include multimorbidity, blood pressure, individ ual morbidities such as osteoporosis and viral infection, and many laboratory parameters rang ing from electrolytes (phosphate), hemogram (hemoglobin), lipid profile, and hormonal panel (parathyroid hormone or vitamin D). In addition, care modality, dialysis modality or duration, dial ysis clearance, or several nutritional measurement parameters (standard global assessment, mini nutritional assessment, and malnutritioninflam mation scores) were similarly neutral regarding their relationship to frailty after accounting for other variables in CKD and ESRD patients. It is possible that these factors are surrogates of other vital pathogenic players of frailty, such as serum albumin, cardiovascular morbidities, CKD sever ities, and residual renal function ( Table 1 ). It will be more appropriate for researchers to account for these instrumental variables that contribute deeply to the development of frailty in subsequent studies aiming to examine frailty risk factors.
Implications for subsequent studies involving frailty in CKD patients
Understanding the risk factors and complications of frailty can be of importance in CKD population from both clinical and public health perspectives. Previous reviews and metaanalyses placed much emphasis on the adverse influences on survival conferred by frailty in CKD patients 10, 11 ; however, emerging studies hint at the diverse organ and functional influences posed by frailty. In addition, there are reports suggesting that frailty signifi cantly modifies the association between other risk features and mortality. 82 Researchers are in the process of devising strategies to combat frailty in CKD patients, especially those with advanced CKD and dialysisdependent ESRD. 83 With the information summarized in this review, we can gain more insight into the beneficial influences of frailtytargeted interventions besides mortality or hospitalization alone. Moreover, by targeting independent risk associates of frailty before or near its onset in CKD patients, we can more effi ciently identify upstream etiologies amenable for reducing frailty, paving the way toward outcome improvement in the future. However, we should still remember that only some of the relationships that we described are causal because 41.9% of studies were crosssectional in nature, precluding overinferences. More than half are singlecenter studies, and there may be centerspecific frailty features that are not generalizable to other popula tions. Nonetheless, we believe that this compre hensive summarization of existing literature can facilitate the design of subsequent frailty studies in CKD patients.
Summary and conclusion
We conducted an extensive literature search and retrieved 62 reports that addressed the risk associ ates or complications of frailty in CKD patients. We found that more than half of these studies focused on dialysisdependent ESRD patients, while only onefifth of these studies examined those with nondialysis CKD or renal transplantation. Fried phenotype with or without modifications was the most common approach for measuring frailty in CKD patients, followed by FRAIL scale and Edmonton frail scale. Contributors to frailty in CKD patients include sociodemographic factors, smoking, higher CKD severity, several organ specific comorbidities, depression, disability, hypo albuminemia, and low testosterone levels. 
